INTRODUCTION
The 70 th Annual National Congress of Indian Psychiatric Society (IPS) will be meeting in February 2017, in Ranchi. It gives an opportunity to reflect on the progress and growth of psychiatry as a vibrant discipline during the last 57 years of my professional life. During these years, psychiatry underwent several spectacular changes. From 13 members in 1947, the membership of IPS has increased to over 6000 as per the latest membership directory of IPS, though the number of qualified psychiatrists in India will be more than 5500. We are training approximately 400 MD and DPM, and DNB students every year. Similarly, with the establishment of psychiatric units/department in over 400 medical colleges, there is rapid growth of PG training centers in India, with a shift from mental hospital training to the general hospital setting. The opening of psychiatric units/departments in almost all medical colleges of India has done more to advance psychiatry than any other diagnostic or therapeutic discovery. Significantly, these developments influenced psychiatry to shift its focus from mental hospital as "European Mental Hospital," and was managed by trained British Psychiatrists, to care for British and other European Patients and was later on managed directly by the Ministry of Health, Government of India since 1954, when it was renamed as Hospital for Mental Diseases.
During 50's and early 60's, insulin coma and electroconvulsive therapy (ECT) as treatment modalities were used commonly in mental hospitals but their popularity was slowly declining, and there was increasing use of few available phenothiazines and tranquilizers which were available in late 50's and early 60's. This changed the entire scene and practice of psychiatric care and service delivery system. It resulted in marked improvement in the clinical atmosphere of the hospitals and gave greater confidence to the psychiatrists. There was better control of patient's destructive behavior, with sharp increase in admission rates and decrease in duration of stay of the patients.
Till 1951, the physical methods of treatment in psychiatry in special hospitals included ECT and insulin coma treatment. Interestingly, even in the UK, which was very advanced in the field of psychiatry at that time, it was reported that within 3 months of onset of disease, effectiveness of treatment by insulin was considered as high as 75%. [1] In some hospitals in India, at Bengaluru and Ranchi, psychosurgery was practiced for which Dr. Egas Moniz was given Noble Prize in Medicine in 1951. Similarly, narcotherapy with the help of sodium pentothal was used to treat psychoneurosis and hysterical cases. [2] There was limited use of many indigenous drugs which were used by some psychiatrists. These drugs were like SILEDIN and Rauvolfia compounds. The use of carbon dioxide therapy in neurosis by some doctors was considered novel. [3] In 1958, chlorpromazine was introduced and later Prochlorperazine and Trifluoperazine were introduced and widely used in schizophrenics. Meprobamate was the only antianxiety drug used for neurosis/anxiety, and there were one or two antidepressants such as imipramine and MAO Inhibitors. Barbiturates, bromides, and injectable paraldehydes were still commonly used.
In 1959, chlordiazepoxide the first effective anti-anxiety drug was introduced, and in early 1960, amitriptyline was available in the market, by the end of 1970, there were about 50 psychotropic and antidepressants drugs available.
This soon enhanced the acceptability of pharmacotherapy for mental disorders and pharmacotherapy was scientifically accepted like in other physical diseases. This resulted in opening of psychiatric units in general hospital setting. There was a regular exchange program of the faculty of Medical College Baroda and University of Edinburgh, which enabled me to setup a modern psychiatry department in a teaching general hospital. It also helped in establishing close collaboration with department of pharmacology and clinical pathology departments which were well equipped. In 1967, during the decade of the progress of Gujarat, the department of psychiatry and department of clinical pathology were highlighted in a Government Documentary. It may be relevant to mention that the first full-fledged independent department of psychiatry was established in 1963 in All India Institute of Medical Sciences (AIIMS) by Prof. D. Satyanand. He started MD psychiatry course in AIIMS, and other institutions in the country followed suit. Dr. D. Satyanand was my teacher in Ranchi before he moved to AIIMS. Till almost 1967-1968, the Department of Psychiatry in PGI Chandigarh, K. G. Medical College, Lucknow, was under the department of medicine. The history of development of general hospital psychiatry is interesting and has been written by the author and others in many publications.
GENERAL HOSPITAL PSYCHIATRY
My initial research work involved the use of TOLBUTAMIDE in place of INSULIN in schizophrenics, in Ranchi [4] when I was working with Professor L. P. Verma at Ranchi, insulin treatment was at that time popular and was considered as a powerful therapeutic method in India. I was also interested in biochemistry of depression. As a part of our ongoing research work program in Medical college, Baroda on biochemical aspects of depression, namely, on 17 hydroxycorticosteroids and estimation of all electrolytes in depression, which was at that time receiving attention from leading researchers in the field. This work was published in both international [5] and national journals. Another area of interest, during this period, was the presence of a pink spot in the urine of schizophrenics which was at that time considered a front area of research in psychiatry. In 1966, an ICMR research project on "Brain Polarization in Depression" was funded by ICMR. After few years, I was appointed to establish another new department in Goa Medical College in 1968. In our laboratory, we tried to resolve the confirmatory and contradictory reports, which had appeared in leading journals with respect to the identification and origin of the pink spot, in the urine of schizophrenics [6, 7, 8] and to see whether the substance dimethoxyphenylethylamine (DMPEA) was present in the cerebrospinal fluid (CSF). Due to the variation of amino acid composition in urine, we thought that CSF would be a better area to work with, in addition to urine and if DMPEA could be detected in the CSF, it would prove more significant.
In sixties, phenothiazine and both tricyclic and monoamine oxidase inhibitors were common psychopharmacological agents available in India for the treatment of acute and chronic schizophrenia and depression. However, extrapyramidal side effects and other side effects such as lactation [9] and tardive dyskinesia were commonly encountered with these drugs. During the search, for newer neuroleptic agents, GO 3315, a new butyrophenone was synthesized at Ciba-Geigy Research Centre, Mumbai. This center was doing outstanding research in the field of clinical pharmacology. This molecule GO 3315 was found to possess an interesting neuroleptic profile in different animal test systems, and it had minimal extrapyramidal effects at pharmacological doses. The toxicity was low in experimental animals. Human tolerability was also found to be acceptable and effective in Phase I and Phase II clinical trials. However, due to reasons not known to the investigators, after Phase I and Phase II clinical studies, in spite of its good therapeutic efficacy and tolerability in schizophrenics, the drug was not introduced in the market by Ciba as CIBA HQ in Basel thought otherwise.
Another interesting molecule developed by Janssen Laboratories was pimozide. Dr. Paul AJ Janssen, who was the director of research at Paul AJ Janssen Lab at Beease in Belgium, who to his credit had over one hundred patents, and who was discoverer of Haloperidol in 1958, and later pimozide and many other drugs. We tried pimozide, before it was marketed even in Europe. The drug showed great promise in selected schizophrenics, who were delusional but not grossly psychotics. This drug was therapeutically very incisive in early schizophrenics and had low EPS side effects. The reasons why this drug could not become popular in North America was because it had shown carcinogenic changes in animal experiments. By early seventies, most of the neuroleptics and antidepressants which were introduced in Western countries were available in India. In India, before marketing any drug, it is made mandatory by Drug Controller Authorities that there should be clinical trials for both its efficacy and safety. The department of psychiatry at Goa was conducting some interesting double-blind studies on newer antipsychotics and antidepressants, etc., such as nomifensine (1980) [10] and dothiepin (1977) . [11] In 60's and 70's many clinical studies from India were published from Mumbai, Goa, Bengaluru, and Lucknow centers.
In 1972, I had the first major exchange of ideas and collaboration with many world leaders in the field of psychopharmacology when I was visiting some leading research centers in Europe and North America. My visit to Europe and North America was more like a pilgrimage to me. I was keen to visit the important centers and meet leading men who were forerunners in the field of psychopharmacology and in biochemical studies and with many of them, I was earlier in correspondence. During this visit, not only did I personally visit their laboratories but also made the acquaintance of a number of leading leaders in the field. This extensive visit of mine to many of these leading centers, stimulated my interest in the field but now the research was getting more and more complex and highly technology based. By this time, I had established a good postgraduate department of psychiatry at Medical College, Goa. In 1974, I was elected as the General Secretary of the Indian Psychiatry Society in Trivandrum and continued for a period of 4 years till 1978. Goa Medical College became active in national scene. The period of 1974-1978 in Indian Psychiatry was quite remarkable in many ways. This was a period when the various IPS Zones were formalized and consolidated. During this period, the various awards like Bhagwat and Marfatia Awards and Dr. D. L. N. Murthy Rao Orations were started. In 1978, for the first time, a W. P. A. regional Symposium was held in AIIMS in New Delhi during the annual conference. It was during this conference that for the first time the Hon'ble Prime Minister of India Sh. Moorarji Desai, inaugurated the meeting. It may be interesting to mention that right from 1947, when IPS was established, two resolutions which were invariably discussed were (1) first, that the Lunacy Act of 1912, has become outdated and it needs to be replaced by a modern Mental Health Act, and (2) second, teaching of psychiatry at undergraduate level is inadequate and psychiatry teaching should find more place in the MBBS curriculum. During the IPS Conference in 1978 in Delhi, while welcoming the Prime Minister, I had politely mentioned that Indian Lunacy Act has become outdated and Government should bring out a new legislation. This had a very positive effect. When I returned to Goa after the conference, there was a telegram from the Health Ministry to send the draft bill to the Ministry at the earliest. The bill was introduced in the Parliament and later referred to the Select Committee. Finally, the Mental Health Act was passed by the Parliament in 1987. Earlier in 1977, in India, the Conferences were inaugurated by the Vice President of India the Governor of West Bengal and the Chief Minister were also the Chief guests. The Membership of the IPS also grew from 250 in 1974 to 500 in 1978. This growth though may look small but was a great achievement at that point. [13, 14] when I served first as a member and later as Chairperson of WPA Committee on "Abuse of Psychiatry." My insight and knowledge in the field of Psychopharmacology were of great help in resolving many ticklish issues. This also gave me good opportunity of working with Prof. By 80's and 90's, it was becoming more clear that many of the controlled studies do not always answer various variations that are actually seen in clinical practice in different cultures. I became more interested in rational use of drugs and also to address the problem of selecting a right neuroleptic or antidepressive drug for a right patient from a large number of such drugs available in the country. It is now becoming an important issue to select a suitable drug. In India, like other developing countries we were equally concerned about the rising cost of drugs. This is a problem, being faced by patients from low-income countries, whereas considering various other pharmacological considerations; their social relevance and cultural background cannot be ignored. From long clinical experience, one is also convinced that the course of disease like Schizophrenia is not uniform and also patients change remarkably in their clinical status and in different cultures in the same countries. These questions are relevant and significant for every clinician, and need to be addressed while considering other emerging social issues such as cost-effectiveness and the role of social environment in the present age of globalization, especially when mental health continues to be a neglected entity in most of the developing countries. Easy availability of effective and safe drugs to the mentally ill, at an affordable cost is a very important issue in most of the countries. I share the belief of many, that with continuing research in the field of psychopharmacology and neuroscience and human genome, it is only a matter of time that we will have more effective and specific drugs, using genetic engineering but the rising cost will deprive the benefit of science to many poor patients who cannot afford the same in the present day ideology of market economics. We have to address this significant ethical, social and economic issue. I believe the last few decades of the last century will be remembered by the availability of new and wide spectrum of drugs, open market policy in the health sector, greater concern about ethical issues and human rights, including concern on stigma of mental illness and the rising cost of drugs. Finally, I have been personally privileged to participate and witness many momentary decisions regarding various programs and policies in India both in the profession and government in partnership with many great names, friends, and colleagues in the advancement of psychiatry in India and also at global level.
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